Strategic Acquisition and Use of Intellectual Property Rights
First written in FY2016. 11 of 13 entries say "Restated". Latest entry: FY2023.
17 other companies' latest entry also says "Restated".
- FY2023RestatedAnnual report
「For these reasons, our group will continue to strategically acquire or use intellectual property rights.」
The company continues its policy of acquiring and using intellectual property rights through joint applications with university researchers and others, acquisitions of rights and trademark and design registrations, among other measures. - FY2023-Q3RestatedAnnual report
「The company recorded revenue from sales of lactoferrin raw materials, licensing income from providing patents relating to lactoferrin enteric-coating technology and applications for improving lipid metabolism, and OEM supplies of health supplements containing lactoferrin and other ingredients.」
The company continues efforts to monetize intellectual property rights and functional materials through lactoferrin raw-material sales, licensing of related patents and OEM supplies. - FY2023-Q2RestatedAnnual report
「The company recorded revenue from sales of lactoferrin raw materials, licensing income from providing patents relating to lactoferrin enteric-coating technology and applications for improving lipid metabolism, and OEM supplies of health supplements containing lactoferrin and other ingredients.」
The company continues to monetize intellectual property rights through lactoferrin raw-material sales, licensing of related patents and OEM supplies. - FY2020RestatedAnnual report
「For these reasons, our group will continue to strategically acquire or use intellectual property rights.」
The company continues its policy of acquiring and using intellectual property rights through joint applications with university researchers, acquisitions of rights and trademark and design registrations, among other measures. - FY2020-Q2RestatedAnnual report
「During the six months ended 30 September, the company recorded revenue from sales of lactoferrin raw materials and from licensing income and other sources arising from the provision of patents relating to lactoferrin enteric-coating technology and applications for improving lipid metabolism.」
The company continues to sell lactoferrin raw materials and recognize licensing income from providing related patents, using intellectual property rights to generate business revenue. - FY2020-Q1RestatedAnnual report
「During the three months ended 30 June, the company recorded revenue from sales of lactoferrin raw materials and from licensing income and other sources arising from the provision of patents relating to lactoferrin enteric-coating technology and applications for improving lipid metabolism.」
The company continues to sell lactoferrin raw materials and recognize licensing income from providing related patents, reaffirming its use of intellectual property rights. - FY2019-Q3RestatedAnnual report
「During the nine months ended 31 December, the company recorded revenue from sales of lactoferrin raw materials and from licensing income and other sources arising from the provision of patents relating to lactoferrin enteric-coating technology and applications for improving lipid metabolism.」
The company continues to sell lactoferrin raw materials and recognize licensing income from providing related patents, using intellectual property rights to generate business revenue. - FY2019-Q2RestatedAnnual report
「During the six months ended 30 September, the company recorded revenue from sales of lactoferrin raw materials and from licensing income and other sources arising from the provision of patents relating to lactoferrin enteric-coating technology and applications for improving lipid metabolism.」
The company continues to provide lactoferrin-related patents and recognize licensing income, reaffirming its policy of using intellectual property rights. - FY2019-Q1RestatedAnnual report
「During the three months ended 30 June, the company recorded revenue from sales of lactoferrin raw materials and from licensing income and other sources arising from the provision of patents relating to lactoferrin enteric-coating technology and applications for improving lipid metabolism.」
The company continues to sell lactoferrin raw materials and recognize licensing income from related patents, reaffirming its use of intellectual property rights. - FY2018RestatedAnnual report
「For these reasons, our group will continue to strategically acquire or use intellectual property rights.」
The company continues its policy of acquiring and using intellectual property rights through joint applications with university researchers, acquisitions of rights and trademark and design registrations, among other measures. - FY2018-Q2RestatedAnnual report
「During the six months ended 30 September, the company recorded revenue from sales of lactoferrin raw materials and from licensing income and other sources arising from the provision of patents relating to lactoferrin enteric-coating technology and applications for improving lipid metabolism.」
The company continues to recognize licensing income from providing lactoferrin-related patents, reaffirming its use of intellectual property rights. - FY2018-Q1AdvancedAnnual report
「The company recorded revenue from sales of lactoferrin raw materials and from licensing income and other sources arising from the provision of patents relating to lactoferrin enteric-coating technology and applications for improving lipid metabolism.」
The provision of lactoferrin-related patents and the resulting recognition of licensing income demonstrate the concrete use of intellectual property rights. - FY2016First statedAnnual report
「We will continue to acquire and use intellectual property rights strategically.」
The policy is to secure rights to research成果 and products through joint filings with university researchers and the acquisition of rights to obtain patents.